Ausdal Financial Partners, Inc. Werewolf Therapeutics, Inc. Transaction History
Ausdal Financial Partners, Inc.
- $1.84 Billion
- Q3 2025
A detailed history of Ausdal Financial Partners, Inc. transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 10,000 shares of HOWL stock, worth $9,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$9,400% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding HOWL
# of Institutions
64Shares Held
22.7MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA6.68MShares$6.28 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.31MShares$4.05 Million19.47% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.41MShares$2.26 Million0.88% of portfolio
-
Bank Of America Corp Charlotte, NC1.83MShares$1.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.59MShares$1.49 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $27.8M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...